Patents by Inventor Mark Bannister

Mark Bannister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of anti-muscarinic agents and calcium channel blockers in combination
    Publication number: 20040028734
    Abstract: An anti-muscarinic agent and a calcium channel blocker are suitable for simultaneous, sequential or separate use in the treatment of a muscle tone disorder or a proliferative, inflammatory or secretory condition.
    Type: Application
    Filed: April 29, 2003
    Publication date: February 12, 2004
    Inventors: Robin Mark Bannister, Nicola Cooper
  • Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
    Patent number: 6677326
    Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: January 13, 2004
    Assignee: Arakis, Ltd.
    Inventors: Hazel Judith Bardsley, Robin Mark Bannister, Julian Clive Gilbert
  • Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
    Publication number: 20030149009
    Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.
    Type: Application
    Filed: October 1, 2002
    Publication date: August 7, 2003
    Inventors: Hazel Judith Bardsley, Robin Mark Bannister, Julian Clive Gilbert
  • Metalloproteinase inhibitors for the treatment of respiratory diseases
    Publication number: 20030099600
    Abstract: Doxycycline is useful for the treatment of a respiratory disease involving tissue destruction.
    Type: Application
    Filed: August 23, 2002
    Publication date: May 29, 2003
    Inventors: Andrew John McGlashan Richards, Robin Mark Bannister, Sharon Adele Chaplin
  • Treatment of respiratory diseases
    Publication number: 20030068280
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Application
    Filed: October 7, 2002
    Publication date: April 10, 2003
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Process for the preparation of galanthamine and its derivatives
    Patent number: 6184004
    Abstract: The subject invention pertains to a process for preparing a compound having a formula (4) or (5), in either optically-enriched or racemic form, wherein R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, aryl, alkaryl, aralkyl and acyl groups. In one embodiment, the process of the invention comprises mixing with a plant extract obtained from crushed daffodil bulbs or crushed snowdrop bulbs an oxidative cyclisation precursor of the compound.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: February 6, 2001
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Robin Mark Bannister, Raymond McCague
  • Resolution
    Patent number: 5892093
    Abstract: A reproducible process for preparing a substantially single enantiomer (R or S) of 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexanoic acid, or an analogue thereof, thereby providing single enantiomer acid for the first time, proceeds by means of a classical salt resolution employing a resolving agent selected from an enantiomer (R or S) of a 1-arylalkylamine and (-)-quinine, and provides novel salts that are readily convertible to verapamil.
    Type: Grant
    Filed: February 7, 1997
    Date of Patent: April 6, 1999
    Assignee: Darwin Discovery Limited
    Inventors: Robin Mark Bannister, Graham Robert Evans, Benjamin Mark Skead
  • Compound and process
    Patent number: 5859279
    Abstract: A process for the preparation of a compound of formula (VI), optionally in enantiomerically-enriched form (R or S), comprises chemoselective reduction of a novel compound of formula (V), wherein Ar.sup.1 and Ar.sup.2 are independently selected from optionally-substituted aromatic or heteroaromatic groups having upto 20 C atoms, Ak is C.sub.1-20 alkyl, and R is H or C.sub.1-20 alkyl.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: January 12, 1999
    Assignee: Darwin Discovery Limited
    Inventors: Robin Mark Bannister, Graham Evans
  • Ring-opening amidation process
    Patent number: 5777138
    Abstract: A process for amidating a 2-azabicyclo?2.2.1!heptan-3-one or a 2-azabicyclo?2.2.1!hept-5-en-3-one by reaction with an amine, to form the corresponding ring-opened amide, is modified by the addition of an additive that accelerates the rate of reaction to an extent that the reaction can be carried out at atmospheric pressure.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: July 7, 1998
    Assignee: Chriroscience Limited
    Inventors: Robin Mark Bannister, Neil Henderson, Graham Ruecroft